Skip to main content

Table 1 Baseline characteristics of the study population

From: Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema

Characteristics

CPFE baseline data

IPF baseline data

Subjects

40

60

Male

38

49

Age (yrs)

56 (31–74)

66 (44 – 78)

Current smokers

2

0

Ex-smokers

38

60

Steroid treatment

18

22

Bronchodilators

15

0

NAC

37

43

Pirfenidone

30

23

Cyclophosphamide

3

0

Azathioprine

7

11

VATS

15

28

FEV1 %predicted

68,6 ± 19

67,8 ± 9,1

FVC %predicted

70,6 ± 21*

62,8 ± 11,4

FEV1/FVC

77,6 ±11,2

83,2 ±10,1

TLC %predicted

69,7 ± 17,9*

57,1 ± 9,1

DLCO %predicted

34,8 ±15*

44,1 ±7,2

MMEF25/75%predicted

69,3 ±35*

79,8 ±19

6MWD (m)

330 ± 168*

402 ± 112

sPAP (by echocardiography) mmHg

37,3 ± 14,5*

32,1 ± 10,9

  1. Data are presented as median (range), No (total) or mean ± SD, unless stated otherwise. *p < 0.05 Abbreviations: 6MWD: 6-minure walking distance, DL CO : Diffusing Capacity for carbon monoxide, FVC: Forced vital capacity, MMEF: maximum midexepiratory flow, sPAP: systolic pulmonary artery pressure, TLC: Total Lung Capacity.